Jun 13, 2025
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
Jan 23, 2025
Rakuten Medical Announces Initiation of Global Phase 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for First-Line Recurrent Head and Neck Cancer
Sep 19, 2024
Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024
Aug 19, 2024
Rakuten Medical Announces New Management Team to Drive the Next Phase of Growth and Innovation
May 29, 2024
Rakuten Medical to Host R&D Day Highlighting Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 in r/m HNSCC
May 24, 2024
Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to be Presented at ASCO 2024
Apr 11, 2024
Rakuten Medical's Poster Presentation at AACR 2024 Demonstrates Reduction in Photoimmunotherapy-induced Edema in Mice with COX-2 Inhibition
Mar 06, 2024
Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox(TM) Platform
Mar 01, 2024
Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023
Jan 11, 2021
Rakuten Medical, Inc. Acquires Key Assets and Manufacturing Technology from LI-COR Biosciences
Jan 07, 2021
Rakuten Medical to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
Aug 19, 2020
Rakuten Medical Announces Acquisition of Medlight SA
Jul 07, 2020
Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate
Jun 22, 2020
Rakuten Medical Presents Data Characterizing how Photoimmunotherapy Induces Cancer Cell Death and Enhances the Immune Response Preclinically
Jun 04, 2020
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments
May 29, 2020
Rakuten Medical Establishes Illuminox(TM) Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance
Jan 10, 2020
Rakuten Medical to Present at the 38th Annual J.P. Morgan Healthcare Conference
Nov 09, 2019
Rakuten Medical Investigational Anti-cancer Therapy Candidate Seen to Activate Immune System Response and Synergize with PD1 Checkpoint Blockade in Animal Models
Sep 30, 2019
Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
May 31, 2019
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence